Cronos Group Inc (TSE:CRON) (NASDAQ:CRON) shares popped Tuesday after the company announced an agreement with cannabis supplier MediPharm Labs Corp (TSE:LABS) (OTCMKTS:MEDIF).

MediPharm will supply Peace Naturals, a wholly owned Cronos subsidiary, with $30 million worth of cannabis concentrate over 18 months with options to increase to as much as $60 million over 24 months.

Today we have dug up three Canadian cannabis stocks that have the lowest price-to-sales ratio [trailing twelve month (TTM)].

Low price-to-sales ratio is indicative of undervaluation. The selected cannabis stocks have a market capitalization in the range of $40 million to $130 million.

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has been authorized by PEI Cannabis and Manitoba Liquor & Lotteries Corporation to supply Emerald-branded cannabis products into those provinces.

Emerald has also fulfilled its first shipments of premium cannabis products to PEI Cannabis and to licensed private retailers in Saskatchewan. 

“We are pleased to have the opportunity to serve additional provinces,” said Dr. Avtar Dhillon, President and Executive Chairman of Emerald. “We believe that our growing nationwide presence reflects the recognition of Emerald as a reliable and consistent cannabis supplier. We look forward to continuing to expand our supply of quality Emerald cannabis products to the Canadian adult-use market.”

Tilray (NASDAQ:TLRY) beat Wall Street's revenue expectations but didn't meet analysts' bottom-line estimates when the company reported its fiscal 2018 fourth-quarter results in March.

But the news was better when Tilray announced its fiscal 2019 first-quarter results after the market closed on Tuesday.

CBD brand ratings by a popular CBD products directory show three brands with top ratings and two brands receiving ratings downgrades. Additionally, three new product ratings have been released this month. Among the top brands is a pure organic brand offered as both a Softgel capsule and as a concentrated liquid, see here https://cbdrevu.com/cbdpure-hemp-oil-cbd/.

Early supply-chain issues in Canada and California aside, the marijuana industry really has the feel of a once-in-a-generation growth opportunity.

It racked up $12.2 billion in global legal sales in 2018, and Wall Street investment bank Cowen Group is calling for up to $75 billion in worldwide sales by 2030. For you math-phobes, that's a compound annual growth rate of almost 17% over the next 12 years.

Walmart, Target among major retailers eyeing CBD product lines: report

The marijuana industry has seen a large amount of incremental shifts over the course of the past few months. In that time, we have not only seen legislation change, but we have also seen the world become more accepting of the miracle substance.

This has led to one of the most inviting investor spaces that we have seen, which has helped to bring market capitalizations even higher. The hopes are high that the industry can continue to flourish as companies move forward with the production of new groundbreaking products.

Today we have identified four Canadian marijuana stocks that have the highest volatility as measured by beta. Beta is a measure of a stock’s volatility in relation to the market. The selected cannabis stocks have a market capitalization in the range of $75 million to $7 billion.

Marijuana stocks are among the most fashionable investments on the TSX. With some stocks in the sector up as much as 70% year to date, they’ve been beating the market with ease. If you’d invested $1,000 in Canopy Growth three years ago, you’d have $23,000 in the bank today — and that’s not the only marijuana stock that has made investors rich. The weed sector as a whole has been beating the market and making many investors happy in the process.